PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin

(2009) T. Hay et al.   CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer

(2009) N McCabe et al.   ONCOGENE

RETRACTED ARTICLE: Poly(Adenosine Diphosphate-Ribose) Polymerase-1 Expression in Cutaneous Malignant Melanomas as a New Molecular Marker of Aggressive Tumor

(2009) Béla Csete et al.   PATHOLOGY & ONCOLOGY RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

Modeling therapy resistance in genetically engineered mouse cancer models

(2008) S ROTTENBERG et al.   DRUG RESISTANCE UPDATES